IMI2 – Call 9

IMI2 – Call 9 was launched on 27 April 2016 with the following topics:

  • Addressing the clinical burden of Clostridium difficile infection (CDI): Evaluation of the burden, current practices and set-up of a European research platform (part of the IMI New Drugs for Bad Bugs (ND4BB) programme)
  • Development of immune tolerance therapies for the treatment of rheumatic diseases
  • Data quality in preclinical research and development
  • Next generation of electronic translational safety
  • Identification and validation of biomarkers for non-alcoholic steatohepatitis (NASH) and across the spectrum of non-alcoholic fatty liver disease (NAFLD)
  • Joint influenza vaccine effectiveness studies

More information on the topics can be found in IMI’s press release and in the Call text. Other relevant documents, including documents for applicants, the list of expert reviewers, and the independent observers’ reports of the evaluations, can be found on the IMI2 Call documents page.



The projects resulting from IMI2 - Call 9 are:

  • COMBACTE-CDI - Combatting bacterial resistance in Europe - Clostridium difficile infections
    factsheet | website
  • DRIVE - Development of robust and innovative vaccine effectiveness
    factsheet | website
  • EQIPD - European quality in preclinical data
    factsheet | website
  • eTRANSAFE - Enhacing translational safety assessment through integrative knowledge management
    factsheet | website
  • LITMUS - Liver investigation: testing marker utility in steatohepatitis
    factsheet | website
  • RTCure - Rheuma tolerance for cure
    factsheet | website


Proposal submission information

  • Proposals submitted: 17
  • Inadmissible & ineligible proposals: 0
  • Proposals recommended for funding: 6
  • Proposals not recommended for funding: 11